Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Gain Therapeutics Inc GANX

Healthcare Biotechnology
Gain Therapeutics, Inc. is a biotechnology company. The Company is focused on developing novel small molecule therapeutics to treat diseases across several therapeutic areas, including, central nervous system (CNS) disorders, lysosomal storage disorders (LSDs), metabolic disorders, and other diseases that can be targeted through protein degradation, such as oncology. The Company’s drug... see more

Recent & Breaking News (NDAQ:GANX)

Gain Therapeutics Presents New Preclinical Data from its Gaucher Disease Program at the 19th Annual WORLDSymposium

GlobeNewswire February 27, 2023

Gain Therapeutics to Participate in Upcoming Scientific and Medical Conferences

GlobeNewswire February 2, 2023

Gain Therapeutics to Present at Sidoti Small-Cap Virtual Investor Conference

GlobeNewswire January 12, 2023

Gain Therapeutics, Inc. Reports Third Quarter 2022 Financial Results and Business Update

GlobeNewswire November 10, 2022

Gain Therapeutics Presents New Preclinical Data Showing Promising Pharmacological Activity in Parkinson's Disease Patient-Derived Dopaminergic Neurons

GlobeNewswire September 26, 2022

Gain Therapeutics Announces Promotion of Matthias Alder to Chief Executive Officer

GlobeNewswire September 20, 2022

Gain Therapeutics Presents New Preclinical Data Demonstrating Potential Disease Modifying Benefits of its Novel Brain Penetrant Small Molecule Candidate GT-02287 in Two Preclinical Models of Parkinson's Disease

GlobeNewswire September 19, 2022

Gain Therapeutics to Present Data at Upcoming Medical Meetings

GlobeNewswire September 8, 2022

Gain Therapeutics To Participate At The H.C. Wainwright 24th Annual Global Investment Conference

GlobeNewswire September 6, 2022

Gain Therapeutics, Inc. Reports Second Quarter 2022 Financial Results and Business Update

GlobeNewswire August 8, 2022

Gain Therapeutics to Participate at the 2022 BTIG Biotechnology Conference

GlobeNewswire August 4, 2022

Gain Therapeutics to Participate at the Jefferies Healthcare Conference

GlobeNewswire June 2, 2022

Gain Therapeutics to Participate at the H.C. Wainwright Global Investment Conference

GlobeNewswire May 18, 2022

Gain Therapeutics, Inc. Reports First Quarter 2022 Financial Results and Business Update

GlobeNewswire May 16, 2022

Gain Therapeutics Presents Positive Preclinical Data On Its Gaucher Disease Program at IWGGD Symposium

GlobeNewswire May 11, 2022

Gain Therapeutics Presents Positive Preclinical Data on its Small Molecule Lead Compound in GBA1 Parkinson's Disease at XXVII IAPRD World Congress

GlobeNewswire May 6, 2022

Gain Therapeutics to Participate in the B. Riley Securities 2022 Virtual Neuro & Ophthalmology Conference

GlobeNewswire April 26, 2022

Gain Therapeutics Presents Positive Data on its Small Molecule Lead Compound in GBA1 Parkinson's Disease at the 2022 Synuclein Meeting

GlobeNewswire April 12, 2022

Gain Therapeutics Presents Additional Confirmatory Data on its Gaucher Disease Program at the 2022 Glycolipid and Sphingolipid Biology Gordon Research Conference

GlobeNewswire March 29, 2022

Gain Therapeutics, Inc. Reports Full Year 2021 Financial Results and Business Update

GlobeNewswire March 24, 2022